Although endometriosis-associated ovarian cancer (EAOC) is considered a separate clinical entity, no specific prognostic biomarkers aid in its management. This has, therefore, been among the factors hindering the development of …
Endometriosis (EMs) is a gynecological inflammatory disease that depends on estrogen. Its chief symptoms include dysmenorrhea, chronic pelvic pain, reduced fertility, and pelvic masses. Although various hormonal therapies and surgical …
Deep endometriosis causes significant pain which adversely affects quality of life and utilises healthcare and wider societal resources. Laparoscopic excision of endometriosis has shown to improve pain symptoms in observational …
Endometriosis, a debilitating disease characterized by chronic inflammation, might be associated with adverse pregnancy outcomes. However, the long-term health implications for offspring born to mothers with endometriosis remain inadequately explored. …
Endometriosis is a complex condition affecting 10% of reproductive-age women worldwide, yet its study has long been hindered by the shortcomings of traditional research models. This review aims to propose …
These are two of the most common gynecologic diseases, affecting 15% to 80% of women of childbearing age diseases. The existing treatments, such as hormonal drugs and selective estrogen receptor …
Pharmacogenetics is an emerging discipline that explores how genetic variants affect drug response, potentially leading to side effects or treatment failure. Although widely applied in other medical specialties, its use …
Endometriosis is a chronic, oestrogen-dependent inflammatory condition affecting approximately 10% of women of reproductive age, frequently associated with chronic pelvic pain, dysmenorrhoea and infertility, substantially impairing quality of life. While …
The immunology of fertilization, implantation and pregnancy is based on a complex balance between maternal immune tolerance and a controlled inflammatory response. Adaptation of the maternal immune system is essential …